Nucleic Acid News and Research

RSS

WHO updates 2026-2027 flu vaccine composition amidst viral evolution

The World Health Organization (WHO) today announced recommendations for the viral composition of influenza (or "flu") vaccines for the 2026-2027 northern hemisphere influenza season.

27 Feb 2026

Nanovaccine design boosts immune attack on HPV tumors

Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure.

11 Feb 2026

New at-home tests accurately detect deadly pet parvoviruses

Pet owners want quick answers when their beloved cat or dog is sick. And if these furry friends are experiencing digestive distress, lethargy and fever, it's important to rapidly rule out serious illnesses like feline panleukopenia (also called feline parvovirus) and canine parvovirus.

10 Feb 2026

How the CDC prepares influenza vaccines for pandemics

CDC scientists outline the comprehensive methodology involved in the development of influenza candidate vaccine viruses.

2 Feb 2026

Aptamer-based wearables revolutionize continuous health tracking

Continuous monitoring of biomarkers is essential for early disease detection, treatment evaluation, and personalized health management, yet most clinical tests rely on invasive, single-point blood sampling. Recent advances in aptamer-based wearable electrochemical sensors offer a promising alternative by enabling real-time, continuous tracking of physiological signals directly in or on the body.

30 Jan 2026

Purdue-developed LENN system enhances stability and targeting of mRNA cancer therapies

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University improves upon traditional methods of targeting bladder cancer cells with messenger RNA (mRNA) therapies.

16 Jan 2026

Scientists reveal how cholera bacteria activate toxin genes in the human gut

Cholera remains a major global public health challenge, with an estimated 1.3 to 4 million cases and tens of thousands of deaths reported worldwide each year.

14 Jan 2026

CRISPR Cas12a3: A precise tool to halt viral protein production

Across all domains of life, immune defenses foil invading viruses by making it impossible for the viruses to replicate. Most known CRISPR systems target invading pathogens' DNA and chop it up to disable and modify genes, heading off infections at the (cellular) pass.

7 Jan 2026

MolGen continues its activities as AgriGenX

Today, we are proud to announce that MolGen’s activities will continue under the name AgriGenX.

From AgriGenX 6 Jan 2026

New rapid test distinguishes real HIV infections from vaccine-related false positives

Since the human immunodeficiency virus (HIV) was identified in 1983, roughly 91.4 million people around the world have contracted the virus and an additional 44.1 million have died from related causes.

3 Dec 2025

Designing better RNA delivery polymers with computational tools

A research team led by professor Olivia Merkel, Chair of Drug Delivery at LMU and co-spokesperson of the Cluster for Nucleic Acid Therapeutics Munich (CNATM) has developed the first integrated platform that combines molecular dynamics (MD) simulations and machine learning (ML) to identify new polymeric materials for therapeutic RNA delivery.

1 Dec 2025

Intranasal nanomedicine shows promise against glioblastoma

Researchers at Washington University School of Medicine in St. Louis, along with collaborators at Northwestern University, have developed a noninvasive approach to treat one of the most aggressive and deadly brain cancers.

22 Nov 2025

Primerdesign launches exsig Mag RapidBead Pro Extraction kit for DNA and RNA

Primerdesign (part of the Novacyt Group), a company focused on the design, manufacture, validation and supply of real-time PCR kits and reagents, today announced the launch of its exsig® Mag RapidBead Pro Extraction kit.

19 Nov 2025

BIOVECTRA and Revolution Biomanufacturing partner to deliver integrated mRNA Design and GMP production services

BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that grants BIOVECTRA access to Revolution Biomanufacturing's proprietary platforms for optimizing untranslated regions (UTRs) and codon usage to enhance mRNA stability and translational efficiency.

6 Nov 2025

Mutated RIG-I receptor causes kidney inflammation through Y-RNA activation

Researchers at the University Hospital Bonn (UKB) and the University of Bonn have discovered how a small, naturally occurring RNA molecule in the kidney activates a mutated immune receptor, triggering a chain reaction.

31 Oct 2025

Scientists capture a near-continuous molecular movie of ribosome formation

Ribosomes are the cell's protein factories, which read the genetic code and assemble the proteins that every organism needs to live. But as far as how ribosomes themselves were formed, tantalizingly little was known.

30 Oct 2025

Research shows the potential of structural nanomedicine in cancer treatment

In a promising advance for cancer treatment, Northwestern University scientists have re-engineered the molecular structure of a common chemotherapy drug, making it dramatically more soluble and effective and less toxic.

29 Oct 2025

Revolutionizing lipid nanoparticle formulations for targeted treatments

Lipid nanoparticles (LNPs) are the delivery vehicles of modern medicine, carrying cancer drugs, gene therapies and vaccines into cells.

24 Oct 2025

New AI system revolutionizes drug design and vaccine development

The rapid advancement of artificial intelligence (AI) is transforming the field of structural biology. In May 2024, DeepMind and Isomorphic Labs launched AlphaFold 3 (AF3), a revolutionary AI system capable of predicting the 3D structures and interactions of proteins, nucleic acids, small molecules, ions, and other biomolecules with remarkable precision.

10 Oct 2025

WHO issues guidance for 2026 flu vaccine formulation in the southern hemisphere

The World Health Organization (WHO) today announced its recommendations for the viral composition of influenza vaccines for use in the 2026 influenza season in the southern hemisphere.

26 Sep 2025